Calithera Biosciences Revenue, Profits - CALA Quarterly Income Statement

Add to My Stocks
$4.7 $0.05 (1.05%) CALA stock closing price Sep 19, 2018 (Closing)

Looking at financial statements, along with the Calithera Biosciences stock price, it's management, its economic moat, and industry competitors forms an important part of fundamental analysis. An income statement is one of the three key financial statements furnished by a company, the other two being the balance sheet and the cashflow statement. When compared with the corresponding income statement from the past, the latest income statement shows how revenue has grown from 5.19M to 17.07M and how operating and non operating activities have impacted the CALA stock. The operating expenses as shown in the Calithera Biosciences profit and loss statement for 2018 Q2 total to $20.81M. This line item shows that the operating expenses has increased compared with last year. Also check: Calithera Biosciences assets and Calithera Biosciences free cash flow.

View and download details of revenue and profits for Calithera Biosciences for latest & last 40 quarters.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Calithera Biosciences Revenues or Net Sales
Cost Of Goods Sold (COGS)----------
Calithera Biosciences Gross Profit
Research & Development Expense17.31M15.49M15.5M10.83M10.14M6.64M6.6M6.31M7.77M7.06M
Selling General & Admin Expense3.5M3.5M3.32M3.07M2.84M3.3M3.02M2.31M2.66M2.59M
Income Before Depreciation Depletion Amortization-3.74M-13.81M-11.55M-6.65M-5.73M-5.75M-9.61M-8.63M-10.44M-9.65M
Depreciation Depletion Amortization----------
Non Operating Income----------
Interest Expense----------
Calithera Biosciences Pretax Income
Provision for Income Taxes----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-3.07M-13.21M-10.97M-6.07M-5.19M-5.59M-9.52M-8.54M-10.36M-9.58M
Extraordinary Items & Discontinued Operations----------
Calithera Biosciences Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS35.87M35.78M35.56M35.48M35.35M25.28M21.05M19.51M18.99M18.39M
Average Shares used to compute Basic EPS35.87M35.78M35.56M35.48M35.35M25.28M21.05M19.51M18.99M18.39M
Income Before Nonrecurring Items-3.08M-13.21M-10.97M-6.07M-5.19M-5.59M-9.52M-8.54M-10.36M-9.58M
Income from Nonrecurring Items----------
Calithera Biosciences Earnings Per Share Basic Net
Calithera Biosciences Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.09-0.37-0.31-0.17-0.15-0.22-0.45-0.44-0.55-0.52
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Before investing one should read a report on Calithera Biosciences stock analysis. It helps to look at the following income statement items:

  • Topline: A growing topline, as seen from the Calithera Biosciences revenue chart, as is the case with Calithera Biosciences indicates a growing business. One needs to compare the QoQ topline or sales growth of CALA stock with its peers like MDWD stock and REPH stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $-3.07M for Calithera Biosciences for 2018 Q2. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called statement of revenue and expense. The CALA financials along with Calithera Biosciences historical stock prices provide a lot of details about the firm.

Calithera Biosciences Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
Dividend Yield